NCT06248528Active, not recruiting
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
To Compare the Survival Differences in Patients With HCC and Portal Vein Tumor Thrombosis Treated With Liver Resection-based Therapy Versus Locoregional-based Therapy: a Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 16 Jul 2025
Brief summary (registry, in English)
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 1076 (actual)
- First submitted
- 31 Jan 2024
- Start date
- 1 Dec 2019
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Chen Xiaoping
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06248528
What you commit to
- Study type: Interventional
- Participants enrolled: 1076
- From 1 Dec 2019 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any persistent serious liver resection or locoregional therapy-related complications
Other illness
- Any history of other malignant tumors or recurrent HCC
- Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency
- Esophageal and/or gastric variceal bleeding within 6 months
Other
- Inability or refusal to comply with the treatment and monitoring
- Participation in other clinical trials
Who the study is looking for
- Aged 18-75 years
- Pathological type is HCC, and with PVTT
- No extrahepatic HCC
- Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 and Child-Pugh grade A for the liver resection group
- ECOG performing status of 0-2 and Child-Pugh grade A-B for the locoregional-based group
- Adequate hematologic and organ function
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.